{"entity":{"id":"eln-risk","kind":"term","name":"ELN 2022 risk classification","aka":["ELN 2022 risk group","ELN 2022 genetic risk group","ELN genetic risk","ELN risk group","ELN favourable risk","ELN intermediate risk","ELN adverse risk","European LeukemiaNet risk","ELN 2017"],"tldr":"The three-tier system (favourable, intermediate, adverse) that decides how aggressively an adult with AML is treated and whether a transplant is recommended.","summary":"The European LeukemiaNet 2022 update classifies AML by genetics: favourable (t(8;21), inv(16), NPM1 without FLT3-ITD, bZIP in-frame CEBPA); intermediate (NPM1 with FLT3-ITD, FLT3-ITD without NPM1, t(9;11)); adverse (TP53, complex/monosomal karyotype, myelodysplasia-related mutations, KMT2A rearrangements other than t(9;11), inv(3), t(6;9)). FLT3-ITD allelic ratio was dropped in 2022 because FLT3 inhibitors changed the outlook. Companion ELN MRD recommendations define molecular and flow thresholds.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Acute_myeloid_leukemia","links":[{"label":"ELN 2022 (Döhner et al., Blood 2022)","url":"https://ashpublications.org/blood/article/140/12/1345/485817"}],"tags":[],"related":[],"cancers":["aml"],"sections":[],"technologies":["cytogenetics-fish","cgp"],"targets":["npm1","flt3","tp53","kmt2a"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Clinical"},"route":"/terms/eln-risk/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/"},{"id":"aml-flt3","kind":"cancer","name":"FLT3-mutated acute myeloid leukaemia","route":"/cancers/aml-flt3/"},{"id":"aml-idh","kind":"cancer","name":"IDH1- and IDH2-mutated acute myeloid leukaemia","route":"/cancers/aml-idh/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"},{"id":"aml-npm1-kmt2a","kind":"cancer","name":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","route":"/cancers/aml-npm1-kmt2a/"},{"id":"aml-secondary","kind":"cancer","name":"Secondary and therapy-related acute myeloid leukaemia","route":"/cancers/aml-secondary/"}],"technology":[{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"},{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"cytogenetics-fish","kind":"technology","name":"Cytogenetics and FISH","route":"/technologies/cytogenetics-fish/"}],"target":[{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/"},{"id":"kmt2a","kind":"target","name":"KMT2A (MLL) rearrangement","route":"/targets/kmt2a/"},{"id":"npm1","kind":"target","name":"NPM1 mutation","route":"/targets/npm1/"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"term":[{"id":"aml-myelodysplasia-related","kind":"term","name":"AML with myelodysplasia-related gene mutations (AML-MR)","route":"/terms/aml-myelodysplasia-related/"},{"id":"flt3-itd-allelic-ratio","kind":"term","name":"FLT3-ITD allelic ratio","route":"/terms/flt3-itd-allelic-ratio/"}],"trial":[{"id":"ratify","kind":"trial","name":"RATIFY (CALGB 10603)","route":"/trials/ratify/"}],"idea":[{"id":"idea-mrd-guided-transplant-aml","kind":"idea","name":"MRD-guided transplant decisions in intermediate-risk AML","route":"/ideas/idea-mrd-guided-transplant-aml/"}]}}